Imatinib, Bevacizumab, and Cyclophosphamide in Patients With Refractory Metastatic Solid Tumors
Status:
Completed
Trial end date:
2011-01-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Imatinib may stop the growth of tumor cells by blocking some of the enzymes needed
for cell growth. Monoclonal antibodies, such as bevacizumab, can block tumor growth in
different ways. Some block the ability of tumor cells to grow and spread. Others find tumor
cells and help kill them or carry tumor-killing substances to them. Drugs used in
chemotherapy, such as cyclophosphamide, work in different ways to stop the growth of tumor
cells, either by killing the cells or by stopping them from dividing. Bevacizumab and
cyclophosphamide may also stop the growth of tumor cells by blocking blood flow to the tumor.
Imatinib and bevacizumab may help cyclophosphamide work better by making tumor cells more
sensitive to the drug. Giving cyclophosphamide once a day together with imatinib and
bevacizumab may kill more tumor cells.
PURPOSE: This phase I trial is studying the side effects and best dose of imatinib when given
together with bevacizumab and cyclophosphamide in treating patients with refractory
metastatic solid tumors.